Campbell & CO Investment Adviser LLC acquired a new position in shares of Acceleron Pharma Inc (NASDAQ:XLRN) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 2,180 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.
Other institutional investors have also recently added to or reduced their stakes in the company. FDx Advisors Inc. purchased a new stake in shares of Acceleron Pharma during the 1st quarter worth $34,000. Ladenburg Thalmann Financial Services Inc. lifted its position in Acceleron Pharma by 33.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,063 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 269 shares during the last quarter. Advisor Group Holdings Inc. purchased a new stake in Acceleron Pharma in the first quarter valued at $60,000. Citizens Financial Group Inc RI purchased a new stake in Acceleron Pharma in the first quarter valued at $90,000. Finally, Macquarie Group Ltd. purchased a new stake in Acceleron Pharma in the fourth quarter valued at $101,000. 88.77% of the stock is owned by institutional investors and hedge funds.
Shares of Acceleron Pharma stock opened at $99.17 on Friday. Acceleron Pharma Inc has a 52-week low of $37.60 and a 52-week high of $110.75. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.04. The company’s 50-day simple moving average is $100.50 and its 200-day simple moving average is $90.57.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.09). Acceleron Pharma had a negative return on equity of 30.14% and a negative net margin of 182.31%. The firm had revenue of $4.30 million for the quarter, compared to analyst estimates of $5.26 million. During the same quarter last year, the firm earned ($0.74) earnings per share. The company’s revenue was up 53.6% compared to the same quarter last year. Equities analysts expect that Acceleron Pharma Inc will post -3.04 EPS for the current year.
In other news, major shareholder Corp /De/ Celgene sold 2,241 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $102.28, for a total transaction of $229,209.48. Following the transaction, the insider now directly owns 7,008,510 shares in the company, valued at $716,830,402.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Habib J. Dable sold 50,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $96.41, for a total transaction of $4,820,500.00. Following the transaction, the chief executive officer now owns 139,324 shares in the company, valued at $13,432,226.84. The disclosure for this sale can be found here. Insiders own 2.50% of the company’s stock.
XLRN has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price target on shares of Acceleron Pharma from $108.00 to $118.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. SVB Leerink boosted their price target on shares of Acceleron Pharma from $127.00 to $132.00 and gave the company an “outperform” rating in a research report on Friday, June 26th. Barclays reissued a “buy” rating and issued a $116.00 price target on shares of Acceleron Pharma in a research report on Tuesday, May 12th. Citigroup boosted their price target on shares of Acceleron Pharma from $136.00 to $137.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Finally, Oppenheimer restated a “buy” rating and issued a $120.00 price objective (up from $115.00) on shares of Acceleron Pharma in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $117.69.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Recommended Story: Economic Reports
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.